NanoRx acquires EnduRx to pair delivery platform with oncology pipeline
What's the deal? NanoRx Science has acquired EnduRx PharmaceuticalsDealroom has a profile for this one. Try Dealroom → through an exchange of shares, the Tucson-based company said on August 5, 2026. EnduRx continues as a wholly owned research and development subsidiary.
What's the endgame? The deal splits roles between the two firms. NanoRx positions itself as the drug delivery platform provider, while EnduRx develops the use cases.
NanoRx offers platform technology to rescue failed drug candidates, extend product lifecycles, and improve safety and efficacy for pharmaceutical partners. It uses the 505(b)(2) regulatory pathway to speed clinical approvals.
What's under the hood? EnduRx's technology implements the "cellular zipcode" concept pioneered by Lasker Awardee and emeritus founder Dr. Erkki Ruoslahti. Peptide ligands guide polymeric nanocarriers to specific organs, tissues, and cells.
Its pipeline targets hard-to-treat cancers including triple-negative breast cancer, high-grade serous ovarian cancer, metastatic prostate cancer, and glioblastoma multiforme. The approach is also adaptable for immunotherapeutics, radiotherapeutics, and nucleic acid constructs.
Why it matters: "NanoRx Science is uniquely positioned to solve complex delivery challenges for our global pharmaceutical partners and to bring safer, more effective therapies to patients faster," said David Loynd, president and chief executive officer of both companies.
EnduRx operates as an industry occupant on the University of Arizona Tucson campus, where it uses core facilities for formulation development. It will keep pursuing non-dilutive funding, building on a history of millions in grant awards from the NIHDealroom has a profile for this one. Try Dealroom → and the Department of Defense CDMRPDealroom has a profile for this one. Try Dealroom →.
The signal: The tie-up reflects a familiar biotech split — a platform technology company paired with a development arm that proves its value across specific indications. NanoRx is already expanding its pipeline toward topical delivery for melanoma and plaque psoriasis.
Read more: AZBio
Image credit: National Institutes of Health (NIH)
